Xiaofan Lu1, Qianyuan Zhang1, Yue Wang1, Liya Zhang1, Huiling Zhao1, Chen Chen1, Yaoyan Wang1, Shengjie Liu1, Tao Lu2, Fei Wang3, Fangrong Yan4. 1. Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. 2. State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. lut163@163.com. 3. Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. blue6923@163.com. 4. Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. f.r.yan@163.com.
Abstract
PURPOSE: Traditional classification of melanoma is widely utilized with little apparent results making the development of robust classifiers that can guide therapies an urgency. Successful seminal research on classification has provided a wider understanding of cancer from multiple molecular profiles, respectively. However, it may ignore the complementary nature of the information provided by different types of data, which motivated us to subtype melanoma by aggregating multiple genomic platform data. METHODS: Aggregating three omics data of 328 melanoma samples, melanoma subtyping was performed by three clustering methods. Differences across subtypes were extracted by functional enrichment, epigenetically silencing, gene mutations and clinical features. Subtypes were further distinguished by putative biomarkers. RESULTS: Functional enrichment of the subtype-specific differential expression genes endowed subtypes new designation: immune, melanin and ion, in which the first subtype was enriched for immune system, the second was characterized by melanin and pigmentation, and the third was enriched for ion-involved transmission process. Subtypes also differed in age, Breslow thickness, tumor site, mutation frequency of BRAF, PTGS2, CDKN2A, CDKN2B and incidence of epigenetically silencing for IL15RA, EPSTI1, LXN, CDKN1B genes. CONCLUSIONS: Skin cutaneous melanoma can be robustly divided into three subtypes by SNFCC+. Compared with the TCGA classification derived from gene expression, the subtypes we presented share concordance, but new traits are excavated. Such a genomic classification offers insights to further personalize therapeutic decision-making and melanoma management.
PURPOSE: Traditional classification of melanoma is widely utilized with little apparent results making the development of robust classifiers that can guide therapies an urgency. Successful seminal research on classification has provided a wider understanding of cancer from multiple molecular profiles, respectively. However, it may ignore the complementary nature of the information provided by different types of data, which motivated us to subtype melanoma by aggregating multiple genomic platform data. METHODS: Aggregating three omics data of 328 melanoma samples, melanoma subtyping was performed by three clustering methods. Differences across subtypes were extracted by functional enrichment, epigenetically silencing, gene mutations and clinical features. Subtypes were further distinguished by putative biomarkers. RESULTS: Functional enrichment of the subtype-specific differential expression genes endowed subtypes new designation: immune, melanin and ion, in which the first subtype was enriched for immune system, the second was characterized by melanin and pigmentation, and the third was enriched for ion-involved transmission process. Subtypes also differed in age, Breslow thickness, tumor site, mutation frequency of BRAF, PTGS2, CDKN2A, CDKN2B and incidence of epigenetically silencing for IL15RA, EPSTI1, LXN, CDKN1B genes. CONCLUSIONS:Skin cutaneous melanoma can be robustly divided into three subtypes by SNFCC+. Compared with the TCGA classification derived from gene expression, the subtypes we presented share concordance, but new traits are excavated. Such a genomic classification offers insights to further personalize therapeutic decision-making and melanoma management.
Authors: Kanika Garg; Margarita Maurer; Johannes Griss; Marie-Charlotte Brüggen; Ingrid H Wolf; Christine Wagner; Niels Willi; Kirsten D Mertz; Stephan N Wagner Journal: Hum Pathol Date: 2016-04-21 Impact factor: 3.466
Authors: F J Li; W J Won; E J Becker; J L Easlick; E M Tabengwa; R Li; M Shakhmatov; K Honjo; P D Burrows; R S Davis Journal: Curr Top Microbiol Immunol Date: 2014 Impact factor: 4.291
Authors: Toshinori Hinoue; Daniel J Weisenberger; Christopher P E Lange; Hui Shen; Hyang-Min Byun; David Van Den Berg; Simeen Malik; Fei Pan; Houtan Noushmehr; Cornelis M van Dijk; Rob A E M Tollenaar; Peter W Laird Journal: Genome Res Date: 2011-06-09 Impact factor: 9.043
Authors: Jason E Hawkes; Pamela B Cassidy; Prashiela Manga; Raymond E Boissy; David Goldgar; Lisa Cannon-Albright; Scott R Florell; Sancy A Leachman Journal: J Dermatol Sci Date: 2012-10-13 Impact factor: 4.563